Ph.D. Alfred P. Spada - 23 Feb 2023 Form 4 Insider Report for Histogen Inc.

Reporting relationship: Executive Vice President and Chief Scientific Officer
Issuer ticker: N/A
Reported as of: 23 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Feb 2023, 15:18:17 UTC
Prior SEC filing: 03 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Susan A. Knudson as attorney-in-fact for Alfred P. Spada, Ph.D.

Key filing fact

Ph.D. Alfred P. Spada filed Form 4 for Histogen Inc. on 27 Feb 2023.

Key facts

This page summarizes Ph.D. Alfred P. Spada's Form 4 filing for Histogen Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Feb 2023, 15:18.

Change

Previous filing in this sequence was filed on 03 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HSTO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +106,793
Change %
Price: $0.000000
Shares after: 106,793
Date: 23 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 106,793
Exercise price: $1.04
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was issued to the Reporting Person as an inducement to employment with the Issuer. It is intended to be an inducement grant in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules.

Footnote F2

1/4 of the shares subject to the option vest one year after the date of grant, on 2/1/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter.

SEC remarks

Executive Vice President and Chief Scientific Officer